Skip to main content
Top

03-02-2025 | Breast Cancer | Research

The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study

Authors: M. Jogendran, J. A. Flemming, M. Djerboua, M. Korzeniowski, B. E. Wilson, S. J. Merchant, S. Bennett

Published in: Breast Cancer Research and Treatment

Login to get access

Abstract

Background

The association between cirrhosis and post-operative breast cancer outcomes has not been explored. We evaluated the association between cirrhosis and surgical outcomes in female patients with breast cancer.

Methods

We performed a retrospective population-based cohort study of female patients undergoing surgery for breast cancer between 2007 and 2018 using health administrative data from Ontario, Canada. Patients were stratified by cirrhosis status. Overall survival (OS) was described using the Kaplan–Meier method and the association between cirrhosis and long-term cancer-specific mortality (CSM) was evaluated using adjusted competing risks regression and subdistribution hazard ratios (sHR).

Results

A total of 902 patients with breast cancer and cirrhosis were compared to 81,514 patients with breast cancer without cirrhosis. The median age at diagnosis was 65 years vs 61 years in patients with and without cirrhosis, respectively (p < .001). The most common etiologies of cirrhosis were metabolic dysfunction-associated steatotic liver disease (n = 595, 66%) and alcohol-associated (n = 143, 16%) liver disease. The median model for end-stage liver disease sodium score was 8 (IQR 6–11, n = 215). Furthermore, cirrhosis was associated with a twofold higher 90-day rate of post-operative mortality (RR 2.82; 95% CI 1.49–5.33). OS was lower in patients with cirrhosis (HR 1.41, 95% CI 1.26–1.58); however, there was no association with CSM (sHR 1.11, 95% CI 0.93–1.32).

Conclusion

This large population-based study demonstrates that patients with cirrhosis have lower OS compared to those without cirrhosis; however, there is no difference in CSM. Their outcomes remain favorable, and they should be considered for curative-intent therapies.
Appendix
Available only for authorised users
Literature
8.
go back to reference Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L (2017) Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group. J Clin Oncol 35(33):3753–3759. https://doi.org/10.1200/JCO.2017.74.4102CrossRefPubMed Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L (2017) Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group. J Clin Oncol 35(33):3753–3759. https://​doi.​org/​10.​1200/​JCO.​2017.​74.​4102CrossRefPubMed
9.
go back to reference Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB (2021) Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. JAMA 326(16):1614–1621. https://doi.org/10.1001/jama.2021.18236CrossRefPubMed Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB (2021) Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. JAMA 326(16):1614–1621. https://​doi.​org/​10.​1001/​jama.​2021.​18236CrossRefPubMed
13.
go back to reference Schultz SE, Rothwell DM, Chen Z, Tu K (2013) Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 33(3):160–166CrossRefPubMed Schultz SE, Rothwell DM, Chen Z, Tu K (2013) Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 33(3):160–166CrossRefPubMed
14.
go back to reference Tu K, Campbell NR, Chen ZL, Cauch-Dudek KJ, McAlister FA (2007) Accuracy of administrative databases in identifying patients with hypertension. Open Med 1(1):e18–e26PubMedPubMedCentral Tu K, Campbell NR, Chen ZL, Cauch-Dudek KJ, McAlister FA (2007) Accuracy of administrative databases in identifying patients with hypertension. Open Med 1(1):e18–e26PubMedPubMedCentral
Metadata
Title
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study
Authors
M. Jogendran
J. A. Flemming
M. Djerboua
M. Korzeniowski
B. E. Wilson
S. J. Merchant
S. Bennett
Publication date
03-02-2025
Publisher
Springer US
Published in
Breast Cancer Research and Treatment
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-025-07612-x

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now